Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation

Core Viewpoint - A lawsuit has been filed against Regeneron Pharmaceuticals, Inc. by an investor alleging violations of securities laws related to undisclosed credit card fee payments that misled investors about the company's sales performance of Eylea [2]. Group 1: Lawsuit Details - The lawsuit claims that Regeneron paid credit card fees to distributors under the condition that they would not charge customers more for using credit cards to purchase Eylea [2]. - It is alleged that these payments effectively subsidized the prices for customers using credit cards, leading to a price concession that lowered Eylea's selling price [2]. - The plaintiff argues that Regeneron's actions misled investors by inflating reported Eylea sales and overstating the Average Selling Price (ASP) reported to federal agencies, thus violating the False Claims Act [2]. Group 2: Investor Information - Shareholders who purchased shares of Regeneron Pharmaceuticals, Inc. prior to November 2023 and continue to hold those shares are encouraged to contact the Shareholders Foundation for further information [1][3].